Bleeding, Chemotherapy Effect, Esophagus Cancer, Venous Thromboembolism
Conditions
Brief summary
This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer. Additionally, the predictive value of the Khorana score and several other VTE and bleeding prediction scores and risk factors will be evaluated.
Detailed description
Patients with cancer are at high risk of venous thromboembolism (VTE), including deep-vein thrombosis and pulmonary embolism. For cancer patients receiving chemotherapy the incidence of VTE is even higher. Several predictive models were previously developed to identify and justify thromboprophylaxis for cancer patietns who are at highest risk of VTE, like the Khorana and PROTECHT score. The Khorana score is a risk-stratification tool to select patients at high risk of VTE for thromboprophylaxis. The PROTECHT score takes cisplatin-based chemotherapy into account in addition of the Khorana score. Thereby, the incidence of bleeding and VTE in patients with esophageal cancer is not clear. This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer. Additionally, the predictive value of the Khorana score and several other VTE and bleeding prediction scores and risk factors will be evaluated.
Interventions
OTHERVenous thromboembolic event, arterial thromboembolic event, bleeding events
Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Esophageal cancer patients * Receiving chemotherapy * Age at least 18 years old
Exclusion criteria
\- Death \<3 months after cancer diagnosis (baseline)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VTE- and bleeding incidence | from start of cancer diagnosis | 6- and 12-month VTE- and bleeding incidence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Predictive performance of VTE risk factors and known prediction models | from start cancer diagnosis | To assess the predictive value of Khorana, modified Vienna-, and PROTECHT score in Predictive performance of VTE risk factors and known prediction models |
| Predictive performance of bleeding risk factors and known prediction models | from start cancer diagnosis | Predictive performance of bleeding risk factors and known prediction models |
| Arterial thromboembolism (ATE) incidence | from start of cancer diagnosis | 6- and 12-month ATE incidence |
Countries
Netherlands
Outcome results
None listed